ArticlePloS one2026
EIF1 coordinates transcriptomic and splicing networks associated with cell cycle dysregulation in diabetic retinopathy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEIF1, an RNA-binding protein implicated in multiple diseases, remains poorly characterized in diabetic retinopathy (DR). This study therefore investigated EIF1 expression and function in an in vitro model of DR pathogenesis.
methodsHuman retinal pigment epithelial cells (ARPE-19) were exposed to 50 mM glucose to model DR. EIF1 was knocked down using siRNA under hyperglycemic conditions, followed by transcriptome sequencing (RNA-seq) to profile differentially expressed genes (DEGs) and alternative splicing events (ASEs). Key findings from RNA-seq were validated by RT-qPCR.
resultsHigh-glucose treatment significantly suppressed cellular proliferation concurrent with EIF1 downregulation, suggesting that hyperglycemia-induced EIF1 depletion may impair retinal pigment epithelial cell functionality. Transcriptome sequencing revealed that EIF1 knockdown induced differential expression in 223 genes in total, comprising 35 upregulated and 188 downregulated genes. Notably, functional enrichment analysis revealed that downregulated genes are significantly enriched in cell cycle-related signaling pathways. Additionally, 1211 differential alternative splicing events were detected, primarily impacting cell cycle and p53 signaling pathways. Further analysis uncovered differentially expressed genes (e.g., BIRC5, MCM4, PLK1, RAD51, MELK, UBE2C, GINS2, and FANCA) and differentially spliced genes (e.g., COP1, TFE3) associated with the cell cycle after EIF1 knockdown. RT-qPCR validation confirmed the differential expression of key DEGs and the altered splicing patterns of COP1 and TFE3, consistent with RNA-seq predictions. These findings suggest that EIF1 may be associated with cell cycle dysregulation through the modulation of both gene expression and alternative splicing.
conclusionsThis study suggests a potential role for EIF1 in DR pathogenesis in an in vitro model, identifying it as a candidate for further investigation. The data point to an association between EIF1 and the regulation of cell cycle-related genes at both the transcriptional and splicing levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.